Gene trio signatures as molecular markers to predict response to doxorubicin cyclophosphamide neoadjuvant chemotherapy in breast cancer patients

Brazilian Journal of Medical and Biological Research

Volumn 43, Issue 12, 2010, Pages 1225-1231

  Barros Filho, M C ^a   Katayama, M L H ^a   Brentani, H ^a,b   Abreu, A P S ^c   Barbosa, E M ^c   Oliveira, C T ^c   Goes J C S ^c   Brentani, M M ^a   Folgueira, M A A K ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b A C CAMARGO CANCER CENTER   (Brazil)

^c Instituto Brasileiro de Controle do Cancer   (Brazil)

Author keywords

Breast neoplasms; Discriminant analysis; Doxorubicin; Drug resistance; Neoadjuvant therapy; Reverse transcriptase polymerase chain reaction

Indexed keywords

BENZODIAZEPINE RECEPTOR; CLEFT LIP AND PALATE ASSOCIATED TRANSMEMBRANE PROTEIN 1; COMPLEMENTARY DNA; CYCLOPHOSPHAMIDE; DOXORUBICIN; HEAT SHOCK REGULATED 1; NOTCH1 RECEPTOR; PROTEIN; PROTEIN NUP210; PROTEIN PRSS11; PROTEIN RLP37A; PROTEIN SMYD2; UNCLASSIFIED DRUG;

ACCURACY; ADJUVANT THERAPY; ADULT; AGED; ARTICLE; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CONTROLLED STUDY; DNA MICROARRAY; FEMALE; GENE EXPRESSION; HUMAN; MULTIPLE CYCLE TREATMENT; NUCLEOTIDE SEQUENCE; PREDICTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; VALIDATION STUDY;

EID: 78650623100     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2010007500135     Document Type: Article

References (20)

1. van der Hage JA, van de Velde CJ, Julien JP, Tubiana-Hulin M, Vandervelden C, Duchateau L. Preoperative chemotherapy in primary operable breast cancer: results from the European Organization for Research and Treatment of Cancer trial 10902. J Clin Oncol 2001; 19: 4224-4237.
2. Bear HD, Anderson S, Brown A, Smith R, Mamounas EP, Fisher B, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
3. Jones RL, Salter J, A'Hern R, Nerurkar A, Parton M, Reis-Filho JS, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat 2010; 119: 315-323.
4. Carey LA, Dees EC, Sawyer L, Gatti L, Moore DT, Collichio F, et al. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes. Clin Cancer Res 2007; 13: 2329-2334.
5. Folgueira MA, Carraro DM, Brentani H, Patrao DF, Barbosa EM, Netto MM, et al. Gene expression profile associated with response to doxorubicin-based therapy in breast cancer. Clin Cancer Res 2005; 11: 7434-7443.
6. Chang JC, Wooten EC, Tsimelzon A, Hilsenbeck SG, Gutierrez MC, Elledge R, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.
7. Hannemann J, Oosterkamp HM, Bosch CA, Velds A, Wessels LF, Loo C, et al. Changes in gene expression associated with response to neoadjuvant chemotherapy in breast cancer. J Clin Oncol 2005; 23: 3331-3342.
8. Bertucci F, Finetti P, Rougemont J, Charafe-Jauffret E, Nasser V, Loriod B, et al. Gene expression profiling for molecular characterization of inflammatory breast cancer and prediction of response to chemotherapy. Cancer Res 2004; 64: 8558-8565.
9. Hess KR, Anderson K, Symmans WF, Valero V, Ibrahim N, Mejia JA, et al. Pharmacogenomic predictor of sensitivity to preoperative chemotherapy with paclitaxel and fluorouracil, doxorubicin, and cyclophosphamide in breast cancer. J Clin Oncol 2006; 24: 4236-4244.
10. Park S, Shimizu C, Shimoyama T, Takeda M, Ando M, Kohno T, et al. Gene expression profiling of ATP-binding cassette (ABC) transporters as a predictor of the pathologic response to neoadjuvant chemotherapy in breast cancer patients. Breast Cancer Res Treat 2006; 99: 9-17.
11. Gianni L, Zambetti M, Clark K, Baker J, Cronin M, Wu J, et al. Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. J Clin Oncol 2005; 23: 7265-7277.
12. Sobral RA, Honda ST, Katayama ML, Brentani H, Brentani MM, Patrao DF, et al. Tumor slices as a model to evaluate doxorubicin in vitro treatment and expression of trios of genes PRSS11, MTSS1, CLPTM1 and PRSS11, MTSS1, SMYD2 in canine mammary gland cancer. Acta Vet Scand 2008; 50: 27.
13. Dallas PB, Gottardo NG, Firth MJ, Beesley AH, Hoffmann K, Terry PA, et al. Gene expression levels assessed by oligonucleotide microarray analysis and quantitative real-time RT-PCR - how well do they correlate? BMC Genomics 2005; 6: 59.
14. Specht K, Harbeck N, Smida J, Annecke K, Reich U, Naehrig J, et al. Expression profiling identifies genes that predict recurrence of breast cancer after adjuvant CMF-based chemotherapy. Breast Cancer Res Treat 2009; 118: 45-56.
15. Koike Folgueira MA, Brentani H, Carraro DM, De Camargo Barros FM, Hirata Katayama ML, Santana de Abreu AP, et al. Gene expression profile of residual breast cancer after doxorubicin and cyclophosphamide neoadjuvant chemotherapy. Oncol Rep 2009; 22: 805-813.
16. Folgueira MA, Brentani H, Katayama ML, Patrao DF, Carraro DM, Mourao NM, et al. Gene expression profiling of clinical stages II and III breast cancer. Braz J Med Biol Res 2006; 39: 1101-1113.
17. Miller WR, Larionov A, Renshaw L, Anderson TJ, Walker JR, Krause A, et al. Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. J Clin Oncol 2009; 27: 1382-1387.
18. Huang J, Perez-Burgos L, Placek BJ, Sengupta R, Richter M, Dorsey JA, et al. Repression of p53 activity by Smyd2-mediated methylation. Nature 2006; 444: 629-632.
19. Parr C, Jiang WG. Metastasis suppressor 1 (MTSS1) demonstrates prognostic value and anti-metastatic properties in breast cancer. Eur J Cancer 2009; 45: 1673-1683.
20. Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med 2006; 355: 560-569.